TAU splice-switching oligonucleotide and pharmaceutical composition for treating or preventing TAU-related disease

MYPI2025003764A0Undetermined Publication Date: 2024-08-10OTSUKA PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025003764
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-02-10
Filing Date
2024-02-09
Publication Date
2024-08-10

AI Technical Summary

Technical Problem

Current treatments for TAU-related diseases, such as tauopathy and Alzheimer's, lack effective methods to reduce TAU protein expression through splicing regulation, as no drug has been marketed to achieve this.

Method used

Development of splice switching oligonucleotides that target TAU pre-mRNA, specifically binding to intron 1B, to alter splicing and decrease TAU protein expression by increasing TAU mRNA containing exon 1B, thereby reducing TAU protein levels.

Benefits of technology

The oligonucleotides effectively increase TAU mRNA containing exon 1B and decrease TAU protein levels, providing a potential therapeutic approach for TAU-related diseases by selectively targeting excitatory neurons to prevent neurodegeneration and excessive neural activity synchronization.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2025003764_DRAWING_001
    Figure PI2025003764_DRAWING_001
  • Figure PI2025003764_DRAWING_002
    Figure PI2025003764_DRAWING_002
  • Figure PI2025003764_DRAWING_003
    Figure PI2025003764_DRAWING_003
Patent Text Reader

Abstract

The present disclosure includes a splice-switching oligonucleotide that binds to intron 1B of TAU pre-mRNA, and a pharmaceutical composition comprising the splice-switching oligonucleotide for treating or preventing a TAU-related disease.
Need to check novelty before this filing date? Find Prior Art

Description

TAU splice-switching oligonucleotides and pharmaceutical compositions for treating or preventing TAU-related diseases

[0001] This application claims priority to Japanese Patent Application No. 2023-019305, the entire contents of which are incorporated herein by reference. The present disclosure includes splice-switching oligonucleotides that target TAU ​​pre-mRNA, and pharmaceutical compositions for treating or preventing TAU-related diseases, comprising the splice-switching oligonucleotides.

[0002] TAU is a microtubule-binding protein that is highly expressed in neurons in the central nervous system and is involved in stabilizing axonal microtubules. Abnormalities in TAU lead to axonal degeneration, neurofibrillary tangles, and TAU mislocalization, resulting in diseases such as tauopathy. Many antisense oligonucleotides called gapmers have been developed to reduce TAU expression. Gapmers regulate the expression of target proteins by inducing cleavage of target RNA using a DNA / RNA duplex by ribonuclease H (RNase H).

[0003] Splicing is the process by which introns are removed from pre-mRNA (pre-mRNA) transcribed from a gene and exons are joined, resulting in the mature mRNA that encodes a protein. Development of splicing-regulating drugs that regulate splicing and restore functional proteins is underway, and these drugs have been put to practical use in the treatment of spinal muscular atrophy. However, no drugs that reduce TAU expression by regulating splicing have been commercially available.

[0004] An object of the present disclosure is to provide a splice-switching oligonucleotide that targets TAU pre-mRNA, and a pharmaceutical composition containing the same for treating or preventing a TAU-related disease.

[0005] In one aspect, the present disclosure provides a splice-switching oligonucleotide that binds to intron 1B of TAU pre-mRNA.

[0006] In one aspect, the present disclosure provides a pharmaceutical composition for treating or preventing a TAU-associated disease, comprising the splice-switching oligonucleotide.

[0007] The present disclosure makes it possible to treat or prevent TAU-associated diseases by altering the splicing of TAU pre-mRNA to reduce the expression of TAU.

[0008] Identification of the sense sequence leading to exon 1B insertion (1). The sequence of the sense strand of TAU pre-mRNA (SEQ ID NO: 38) to which the oligonucleotide complements, the positions of the primers (118, 120) used for RT-PCR, and a representative TAU transcript are shown. Identification of the sense sequence leading to exon 1B insertion (2). iPS cells were treated with 1 μM of oligonucleotides (comparison compound 1, Scramble, compounds 2-5) for 15 days, and RT-PCR was performed for TAU (top) and control ACTB (bottom). Synthetic DNA template was used as a positive PCR control (right). The predicted transcripts based on molecular weight are shown on the right. Confirmation of exon structure by Sanger sequencing (1). Three bands at approximately 335 bp, 235 bp, and 200 bp observed in the compound 4-treated sample in Figure 1B were excised from the gel and cloned into plasmids. The presence of the insert was confirmed by PCR and electrophoresis. Confirmation of exon structure by Sanger sequencing (2). The nucleotide sequence of clone 2 in Figure 2A (top) evaluated by Sanger sequencing. The results of the single end from the forward primer are shown. The stop codon (TGA) contained in exon 1B is underlined and highlighted with "STOP." Confirmation of exon structure by Sanger sequencing (3). The nucleotide sequence of clone 10 in Figure 2A (middle) evaluated by Sanger sequencing. The results of the single end from the forward primer are shown. The stop codon (TGA) contained in exon 1B is underlined and highlighted with "STOP." Confirmation of exon structure by Sanger sequencing (4). The nucleotide sequence of clone 24 in Figure 2A (bottom) evaluated by Sanger sequencing. The results of the single end from the forward primer are shown. Construction of a qPCR system to selectively quantify TAU productive and nonproductive mRNAs (1). (Top) The positions of the primers (arrows) and probes (lines) designed to selectively detect TAU ​​nonproductive mRNA are shown. (Bottom) Various synthetic template DNAs were serially diluted, and qPCR was performed using the TAU nonproductive mRNA detection kit. The resulting Ct values ​​and copy numbers are shown in the graph. 10 6When the Ct value for a copy was greater than 40 and could not be calculated, it was indicated as ND. Construction of a qPCR to selectively quantify TAU productive mRNA and TAU nonproductive mRNA (2). (Top) The positions of the primers (arrows) and probe (line) designed to selectively detect TAU ​​productive mRNA are indicated. (Bottom) Various synthetic DNA templates were serially diluted, and qPCR was performed using the TAU productive mRNA detection set. The resulting Ct values ​​and copy numbers are shown in the graph. Construction of a qPCR to selectively quantify TAU productive mRNA and TAU nonproductive mRNA (3). (Top) The positions of the primers (arrows) and probe (line) designed to selectively detect TAU ​​pre-mRNA are indicated. (Bottom) Various template synthetic DNAs were serially diluted and qPCR was performed using a TAU pre-mRNA detection kit. The resulting Ct values ​​and copy numbers are shown in the graph. Detailed analysis of the splice-switching activity of oligonucleotides (1). The sense strand sequence (SEQ ID NO: 38) of TAU pre-mRNA to which compounds 1 to 6 complement, and TAU transcripts (productive and nonproductive mRNAs linked to exon 4) are shown. Detailed analysis of the splice-switching activity of oligonucleotides (2). iPS cells were treated with 1 μM oligonucleotides (Scramble, comparative compound 1, and compounds 1 to 6) for 15 days, and the copy numbers of nonproductive and productive mRNAs and ACTB were quantified. After correcting for ACTB, the graph was created so that the untreated group represented 100%. Absolute quantification of TAU protein. (Top) Shows TAU protein variants expressed in the central nervous system. Combinations of two, one, or zero N-terminal inserts and four or three C-terminal microtubule-binding domain inserts result in a total of six variants. Common abbreviations and amino acid numbers are listed. (Bottom) The longest 2N4R TAU recombinant protein (cross, dotted line) and the shortest 0N3R TAU recombinant protein (circle, solid line) were quantified using a commercially available HTRF® kit, and the recombinant protein concentrations and resulting fluorescent signals were plotted. Concentration-dependence study I (1).iPS neurons were treated with a predetermined concentration of compound 7 for 15 days, and various expression levels were quantified. Concentration-dependence test I (2). iPS neurons were treated with a predetermined concentration of compound 8 for 15 days, and various expression levels were quantified. Concentration-dependence test I (3). iPS neurons were treated with a predetermined concentration of gapmer (comparison compound 1) for 15 days, and various expression levels were quantified. Identification of neurons with increased TAU nonproductive mRNA (1). iPS neurons were treated with 3 μM compound 7 or 8 for 15 days, and TAU nonproductive mRNA was visualized. The scale bar indicates 10 μm. Identification of neurons with increased TAU nonproductive mRNA (2). After the procedure shown in Figure 7A, cells were immunostained with antibodies against NeuN, a marker for mature neurons, and GABA, a marker for inhibitory neurons. The scale bar indicates 10 μm. scRNA-seq (1). The schedule for oligonucleotide treatment of iPS neurons is shown. scRNA-seq (2). The results of two-dimensional clustering performed by dimensionally reducing the gene expression profile of each cell are shown. scRNA-seq (3). A heat map of the expression of marker genes in each cluster is shown. scRNA-seq (4). A violin plot shows the TAU (MAPT) expression levels in the excitatory and inhibitory neuron populations for gapmer (comparison compound 1), compound 7, or compound 8 treatment groups. scRNA-seq (5). The mean and 95% confidence intervals for the difference in the percentage of TAU (MAPT) expression levels in excitatory and inhibitory neurons between compound-treated groups, as determined by bootstrap analysis. (1). The schedule for oligonucleotide treatment of iPS neurons and iPS astrocyte cultures is shown. (2) Suppression of excessive synchronization of neural activity by reduction of endogenous TAU protein. Raster plots of pre (left) and post (right) KCl treatment are shown. Individual thin lines: spikes, individual thick lines: bursts (= generated by continuous spikes lasting several seconds), squares: network bursts, and spikes: spike histograms. (3) Suppression of excessive synchronization of neural activity by reduction of endogenous TAU protein. The number of network bursts in the pre-treatment period was corrected to 100%, and the post-treatment percentage is shown.N = 6 wells. Paired T-tests: *<0.05, **<0.01. Concentration-dependence test II (1). iPS neurons were treated with a predetermined concentration of compound 7 for 15 days, and various expression levels were quantified. Concentration-dependence test II (2). iPS neurons were treated with a predetermined concentration of compound 8 for 15 days, and various expression levels were quantified. Concentration-dependence test II (3). iPS neurons were treated with a predetermined concentration of gapmer (comparative example compound 2) for 15 days, and various expression levels were quantified. Concentration-dependence test II (4). iPS neurons were treated with a predetermined concentration of gapmer (comparative example compound 3) for 15 days, and various expression levels were quantified.

[0009] Unless otherwise specified, terms used herein have the meanings commonly understood by those skilled in the art of organic chemistry, medicine, pharmacology, molecular biology, microbiology, etc. Definitions of some terms used herein are provided below, but these definitions take precedence over common understandings in this specification.

[0010] The present disclosure relates to oligonucleotides that can reduce the amount of TAU protein by altering the splicing of TAU pre-mRNA.

[0011] TAU is a microtubule-associated protein that is highly expressed in neurons in the central nervous system and is involved in stabilizing axonal microtubules. Starting from the N-terminus, TAU can be divided into four regions: the N-terminal region, the proline-rich region, the microtubule-binding region, and the C-terminal region. The human TAU gene is located on chromosome 17 and is also known as the MAPT (microtubule-associated protein tau) gene. TAU pre-mRNA refers to the unspliced ​​mRNA transcribed from the TAU gene. The human TAU gene has been reported to have at least 16 exons, and alternative splicing of TAU pre-mRNA results in six TAU protein variants ranging from 352 to 441 amino acids in length in humans. The N-terminal region contains two inserts, N1 and N2, encoded by exons 2 and 3, respectively. The microtubule-binding region is divided into four domains, R1 to R4, with R2 encoded by exon 10. There are three types of N-terminal region: 0N type, in which both exons 2 and 3 are deleted; 1N type, in which only exon 2 is present; and 2N type, in which both exons 2 and 3 are present. There are two types of microtubule-binding region: 3R type, in which exon 10 is deleted; and 4R type, in which exon 10 is present. The combinations of these types result in six variants.

[0012] Splicing is a process in which introns are removed from pre-mRNA transcribed from a gene and exons are joined. In splicing, RNA-binding proteins (RBPs) recognize exon-specific splicing enhancer (ESE) sequences, exon-specific splicing silencer (ESS) sequences, intron-specific splicing enhancer (ISE) sequences, or intron-specific splicing silencer (ISS) sequences in exons or introns, and regulate the skipping or inclusion (insertion) of exons or introns.

[0013] The present inventors focused on a transcript registered in the database as ENST00000571311.5, in which 135 nucleotides (nt) (SEQ ID NO: 1), which would normally be recognized as an intron, were recognized as an exon and inserted between exon 1 and exon 2. Herein, the region of DNA or RNA corresponding to this inserted sequence is referred to as exon 1B. Because the insertion of exon 1B results in the appearance of a premature termination codon, TAU protein is not produced from mRNA containing exon 1B. It is assumed that this mRNA is degraded by nonsense-mediated mRNA decay (NMD). In the present disclosure, mRNA that produces the protein encoded by a gene is referred to as productive mRNA, and mRNA that does not produce the protein is referred to as nonproductive mRNA.

[0014] As used herein, exon 1B of TAU pre-mRNA (also referred to as TAU exon 1B) refers to a region of TAU pre-mRNA that corresponds to the sequence of SEQ ID NO: 1 when the TAU pre-mRNA and the sequence of SEQ ID NO: 1 are optimally aligned (maximum identity), and is not limited to a region consisting of the sequence of SEQ ID NO: 1. As used herein, when a base sequence represents an RNA sequence, T in the base sequence is understood to mean U, and when an RNA sequence is aligned with a base sequence described herein, T in the base sequence is considered to be U. TAU exon 1B AGGGGAGTGAATTCACTGAGCTGAGAGCTGAGGAACCATTGATCTGATGGCTGAGACACCACTGGGAAGACTGGAGAGGCTTTTCTGGGCATGCAGTGCCAGGCACAGGAGGAGCTGAGGGAAGATGACTAAGAG (SEQ ID NO: 1)

[0015] The oligonucleotides of the present disclosure can bind to TAU pre-mRNA and alter its splicing, thereby increasing the amount of TAU mRNA containing exon 1B and decreasing the amount of TAU protein. The oligonucleotide binds to the pre-mRNA through hydrogen bonding between its nucleoside base and the complementary nucleoside base of the pre-mRNA. The term "oligonucleotide can bind to pre-mRNA" means that the oligonucleotide has a degree of complementarity with the pre-mRNA that allows it to form a double strand, but the oligonucleotide does not necessarily have a sequence that is completely complementary to the sequence of the pre-mRNA. Examples of complementary base pairs include adenine (A) and thymine (T), adenine (A) and uracil (U), and cytosine (C) and guanine (G).

[0016] In the present disclosure, oligonucleotides that can alter splicing are referred to as splice-switching oligonucleotides (SSOs). That is, the term "oligonucleotide" as used herein encompasses SSOs, and descriptions of "oligonucleotides" as used herein also apply to SSOs. Oligonucleotides that function as SSOs do not induce degradation of TAU pre-mRNA by RNase H. RNase H is an enzyme that specifically cleaves the RNA strand of a DNA / RNA duplex. Unlike SSOs, antisense oligonucleotides called gapmers induce degradation of target mRNAs by RNase H. As described in Experiment 5 of the Examples, if nonproductive mRNA increases while productive mRNA decreases in cells treated with an oligonucleotide, it is clear that the oligonucleotide functions as an SSO and does not induce degradation of TAU pre-mRNA by RNase H.

[0017]

[0018] In some embodiments, the oligonucleotide comprises or consists of a sequence complementary to a sequence having 70%, 75%, 80%, 85%, 90%, or 95% or greater sequence identity to the sequence 5'-GGCAAAGAATTCAGAAATT-3' (SEQ ID NO: 3), or a sequence complementary to the sequence 5'-GGCAAAGAATTCAGAAATT-3' (SEQ ID NO: 3), or a sequence in which 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 1 or 2 bases have been altered in the sequence of SEQ ID NO: 3. The sequence of SEQ ID NO: 3 corresponds to the sequence from base 6 to base 24 of the sense strand of intron 1B of the TAU pre-mRNA set forth in SEQ ID NO: 2.

[0019] In some embodiments, the oligonucleotide comprises or consists of a sequence complementary to a sequence consisting of at least 13 consecutive bases (i.e., 13, 14, 15, 16, 17, 18, or 19 bases) in the sequence 5'-GGCAAAGAATTCAGAAATT-3' (SEQ ID NO: 3).

[0020] In certain embodiments, the oligonucleotide comprises or consists of a sequence complementary to a sequence having 70%, 75%, 80%, 85%, 90%, or 95% or more sequence identity to the sequence 5'-GGCAAAGAATTCAGAAAT-3' (SEQ ID NO: 4) or 5'-GCAAAGAATTCAGAAATT-3' (SEQ ID NO: 5); or The nucleic acid sequence comprises or consists of a sequence complementary to the sequence of 5'-GGCAAAGAATTCAGAAAT-3' (SEQ ID NO: 4) or 5'-GCAAAGAATTCAGAAATT-3' (SEQ ID NO: 5), or a sequence complementary to a sequence in which 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 1 or 2 bases have been modified in the sequence of 5'-GGCAAAGAATTCAGAAAT-3' (SEQ ID NO: 4) or 5'-GCAAAGAATTCAGAAATT-3' (SEQ ID NO: 5).

[0021] In certain embodiments, the oligonucleotide comprises or consists of a sequence complementary to the sequence 5'-GGCAAAGAATTCAGAAAT-3' (SEQ ID NO: 4) or 5'-GCAAAGAATTCAGAAATT-3' (SEQ ID NO: 5).

[0022] In one embodiment, the oligonucleotide comprises or consists of a sequence complementary to the sequence 5'-GCAAAGAATTCAGAAATT-3' (SEQ ID NO: 5).

[0023] In one embodiment, the oligonucleotide comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, or 95% or more sequence identity to the sequence 5'-ATTTCTGAATTCTTTGCC-3' (SEQ ID NO: 6) or 5'-AATTTCTGAATTCTTTGC-3' (SEQ ID NO: 7), or a sequence in which 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 1 or 2 bases are modified in the sequence of SEQ ID NO: 6 or SEQ ID NO: 7.

[0024] In certain embodiments, the oligonucleotide comprises or consists of the sequence 5'-ATTTCTGAATTCTTTGCC-3' (SEQ ID NO: 6) or 5'-AATTTCTGAATTCTTTGC-3' (SEQ ID NO: 7).

[0025] In one embodiment, the oligonucleotide comprises or consists of the sequence 5'-AATTTCTGAATTCTTTGC-3' (SEQ ID NO: 7).

[0026] As used herein, an oligonucleotide refers to a compound containing multiple nucleosides linked together by internucleoside linkages. A nucleoside refers to a compound containing a sugar component and a base component. Nucleosides include ribonucleosides and deoxyribonucleosides. The oligonucleotides of the present disclosure may contain any nucleoside and internucleoside linkage known in the art and can be produced by known nucleic acid synthesis techniques. In the oligonucleotides of the present disclosure, the nucleosides may be natural or non-natural nucleosides, and the internucleoside linkages may be natural or non-natural internucleoside linkages. Oligonucleotides containing non-natural nucleosides and / or non-natural internucleoside linkages are also referred to as modified oligonucleotides.

[0027] Nucleosides can be natural or unnatural nucleosides. Natural nucleosides refer to compounds that contain natural sugar moieties and natural base moieties, and unnatural nucleosides refer to compounds that contain unnatural sugar moieties and / or unnatural base moieties.

[0028] A natural sugar moiety is a furanose-type ribose or 2'-deoxyribose. An unnatural sugar moiety can include modifications of one or more atoms of the ribofuranose ring (e.g., one or more positions selected from the 2', 4', and 5' positions), bridging two atoms of the ribofuranose ring (bicyclic sugars), replacing the oxygen atom (O) of the ribofuranose ring with another atom (e.g., S, N, or C), and replacing the ribofuranose ring with another structure, and any combination thereof.

[0029] Modifications of the ribofuranose ring include halogen, amino, thio, alkyl, alkenyl, alkynyl, O-alkyl, O-alkenyl, O-alkynyl, S-alkyl, S-alkenyl, S-alkynyl, N-alkyl, N-alkenyl, N-alkynyl, allyl, O-allyl, S-allyl, N-allyl, O-alkyl-O-alkyl (wherein alkyl, alkenyl, alkynyl, and aryl can be substituted or unsubstituted alkyl, alkenyl, alkynyl, and aryl), etc. In some embodiments, modifications of the ribofuranose ring include 2'-F, 2'-OCH 3 (O-methyl), 2'-O(CH 2 ) 2 OCH 3 (MOE), 4'-S, 5'-vinyl, and 5'-methyl.

[0030] Nucleosides containing a bicyclic sugar include nucleosides in which the 2'- and 4'-atoms are bridged, such as LNA (Locked Nucleic Acid / 2'-O,4'-C-Methylene-bridged Nucleic Acid), AmNA (Amido-Bridged Nucleic Acid), and ENA (Ethylene-bridged Nucleic Acid).

[0031] Unnatural nucleosides may be compounds in which the sugar moiety is replaced with an acyclic structure, such as peptide nucleic acids (PNAs).

[0032] Natural bases are adenine (A), thymine (T), cytosine (C), guanine (G), and uracil (U). Unnatural bases include substitutes for natural bases, such as 5-methylcytosine, 5-hydroxymethylcytosine, 6-methyladenine, 6-methylguanine, 4-thiouracil, and 5-fluorouracil. Unless otherwise specified, the sequence of an oligonucleotide is represented herein using natural bases, and an oligonucleotide defined by such a sequence also encompasses oligonucleotides containing unnatural bases corresponding to the natural bases.

[0033] The internucleoside linkages can be natural or non-natural internucleoside linkages. Natural internucleoside linkages are phosphodiester linkages. Non-natural internucleoside linkages include phosphotriester, phosphorothioate, boranophosphate, phosphorodithioate, alkylphosphonate, phosphorylguanidine, methylphosphonate, methylenemethylamino (-CH 2 -N(CH 3 )-O-CH 2 -), thiodiester (-O-C(O)-S-), thionocarbamate (-O-C(O)(NH)-S-), siloxane (-O-Si(H) 2 —O—), and N,N′-dimethylhydrazine (—CH2-N(CH 3 )-N(CH 3 )-) is included.

[0034] An oligonucleotide may contain two or more types of nucleosides and / or two or more types of internucleoside linkages. When an oligonucleotide contains two or more types of nucleosides and / or two or more types of internucleoside linkages, the proportions and order of each nucleoside and internucleoside linkage are arbitrary.

[0035] To enable an oligonucleotide to function as an SSO, the type of nucleoside and / or the internucleoside bond can be selected so as not to induce RNA degradation by RNase H. Those skilled in the art can appropriately select the type and position of nucleosides and internucleoside bond necessary for an oligonucleotide to function as an SSO. In certain embodiments, the oligonucleotide does not contain 6 or more, 5 or more, 4 or more, 3 or more, or 2 or more, preferably 6 or more, 5 or more, or 4 or more consecutive natural deoxyribonucleosides. A gapmer may be an oligonucleotide consisting of a central region containing 4 or more, 5 or more, or 6 or more consecutive natural deoxyribonucleosides and regions (referred to as 5'-wing regions and 3'-wing regions) of 2 bases or more in length (e.g., 2 to 10 bases, 3 to 7 bases, or 4 to 5 bases in length) containing at least one unnatural nucleoside located at the 5'-end and 3'-end of the central region. Therefore, in certain embodiments, the oligonucleotide of the present disclosure is not an oligonucleotide consisting of a central region containing four or more, five or more, or six or more consecutive natural deoxyribonucleosides and regions of two or more bases in length (e.g., 2 to 10 bases in length, 3 to 7 bases in length, or 4 to 5 bases in length) containing at least one unnatural nucleoside at the 5'- and 3'-ends of the central region.

[0036] The oligonucleotides may be 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 bases in length or more. In certain embodiments, the oligonucleotides are 13-23, 14-22, 15-21, or 16-20 bases in length, e.g., 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 bases in length or less, where the upper and lower limits can be independently selected.

[0037] In this specification, a sequence "containing" a predetermined base sequence is used to mean a sequence in which one or more bases are added to the predetermined base sequence, and a sequence consisting of the predetermined base sequence.

[0038] With respect to base sequences, sequence identity refers to the percentage of matching bases between two sequences aligned optimally (maximum matching). Sequence identity is calculated using the following formula: sequence identity (%) = [(matching bases between two sequences) / (alignment length)] × 100. Sequence identity can be calculated using programs such as FASTA and BLAST.

[0039] The base modification includes deletion, substitution, insertion, and addition of bases. The modification may be any one of deletion, substitution, insertion, and addition, or a combination of two or more thereof. For example, in the modification of two or more bases, each modification is independently selected from deletion, substitution, insertion, and addition.

[0040] In some embodiments, the oligonucleotide increases the amount of TAU mRNA containing exon 1B by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 250%, 300%, 350%, or 400% compared to a control.

[0041] In certain embodiments, the oligonucleotide reduces the amount of TAU protein by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% compared to a control.

[0042] Whether an oligonucleotide can alter splicing so as to increase the amount of TAU mRNA containing exon 1B can be confirmed by quantitative PCR (qPCR) as described in Experiment 5 of the Examples. qPCR uses a set of a forward primer designed to span between exon 1B and exon 4 and a reverse primer designed within exon 4, and a set of a forward primer designed to span between exon 1 and exon 4 and a reverse primer designed within exon 4. If oligonucleotide treatment increases the amplification product of the former primer set and decreases the amplification product of the latter primer set, it is determined that the oligonucleotide can alter splicing so as to increase the amount of TAU mRNA containing exon 1B.

[0043] In some embodiments, the oligonucleotide selectively increases the amount of TAU mRNA containing exon 1B in excitatory neurons. As used herein, "an oligonucleotide selectively increases the amount of TAU mRNA containing exon 1B in excitatory neurons" means that the increase in the amount of TAU mRNA containing exon 1B in excitatory neurons by the oligonucleotide is greater than the increase in the amount of TAU mRNA containing exon 1B in inhibitory neurons. Examples of excitatory neurons include glutamatergic neurons, and examples of inhibitory neurons include GABAergic neurons. Whether an oligonucleotide can selectively increase the amount of TAU mRNA containing exon 1B in excitatory neurons can be confirmed by visualizing TAU mRNA in excitatory neurons and inhibitory neurons using a probe capable of detecting TAU mRNA containing exon 1B, as described in Experiment 8 of the Examples.

[0044] Whether an oligonucleotide can reduce the amount of TAU protein can be confirmed by a conventional quantitative method that is thought to reflect the amount of protein, such as qPCR. In some embodiments, the oligonucleotide can selectively reduce the amount of TAU protein in excitatory neurons. By selectively reducing the amount of TAU protein in excitatory neurons, it is possible to suppress neurodegeneration caused by excessive neural activity synchronization while avoiding side effects caused by unnecessary TAU inhibition. As used herein, "an oligonucleotide selectively reduces the amount of TAU protein in excitatory neurons" means that the reduction in the amount of TAU protein in excitatory neurons by the oligonucleotide is greater than the reduction in the amount of TAU protein in inhibitory neurons. Examples of excitatory neurons include glutamatergic neurons, and examples of inhibitory neurons include GABAergic neurons. Whether an oligonucleotide can selectively reduce the amount of TAU protein in excitatory neurons can be confirmed by, for example, measuring the expression level of TAU mRNA, which is thought to correlate with the amount of TAU protein, using single cell RNA sequencing (scRNA-seq) as described in Experiment 9 of the Examples, and comparing the expression changes in excitatory neurons and inhibitory neurons between oligonucleotide-treated groups.

[0045] In one embodiment, the oligonucleotide is used to target a TAU containing exon 1B in excitatory neurons. The increase in mRNA level or decrease in TAU protein level is at least 5%, 6%, 7%, 8%, 9%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 210%, 220%, 230%, 240%, 250%, 260%, 270%, 280%, 290%, 300%, 310%, 320%, 330%, 340%, 350%, 360%, 370%, 380%, 390%, or 400% greater than the increase or decrease in inhibitory neurons.

[0046] In some embodiments, the increase in the amount of TAU mRNA or decrease in the amount of TAU protein containing exon 1B in excitatory neurons by the oligonucleotide is at least 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2.0-fold, 2.1-fold, 2.2-fold, 2.3-fold, 2.4-fold, 2.5-fold, 2.6-fold, 2.7-fold, 2.8-fold, 2.9-fold, or 3.0-fold greater than the increase or decrease in inhibitory neurons.

[0047] In certain embodiments, the oligonucleotide is selected from the following:

[0048] The oligonucleotides of the present disclosure can reduce the amount of TAU protein and can be used to treat or prevent TAU-related diseases. As used herein, a TAU-related disease refers to a disease or condition in which the accumulation or mislocalization of TAU is involved in the onset or progression of the disease.

[0049] TAU-associated diseases include tauopathies and epilepsy. TAU-associated diseases also include dementia, such as Alzheimer's dementia (AD), vascular dementia, and dementia with Lewy bodies (DLB), Parkinson's disease, amyotrophic lateral sclerosis (ALS), Down syndrome (Down), Pick's disease (Pick), and chronic traumatic encephalopathy (CHA). These include progressive encephalopathies (CTE), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and myotonic dystrophy type 1 (DM1). TAU-associated diseases also include Dravet syndrome, tuberous sclerosis complex (TSC), episodic ataxia (EA) (e.g., EA-1 and EA-2), cortical dysplasia-focal epilepsy (CDFE) syndrome, and developmental and epileptic encephalopathy (DEE) 14 or 18. TAU-related diseases also include ophthalmic diseases such as glaucoma and age-related macular degeneration (AMD).

[0050] Treating TAU-related disease includes ameliorating one or more symptoms or manifestations of the disease and inhibiting its progression. Preventing TAU-related disease includes inhibiting or delaying the onset of the disease.

[0051] The oligonucleotide is administered to a subject in an amount (referred to herein as an effective amount) capable of exerting the desired effect (e.g., therapeutic or preventive effect against TAU-related diseases). The dosage is appropriately selected depending on the age, body weight, health condition, etc. of the subject. The oligonucleotide may be administered at a dose of, for example, 0.01 mg to 10 mg, 0.01 mg to 5 mg, 0.01 mg to 1 mg, 0.01 mg to 0.5 mg, or 0.05 mg to 0.5 mg per kg of body weight. The oligonucleotide may be administered multiple times, and may be administered daily, once every day or several days, once every week or several weeks, once every month or several months, or once every several years or lifetime. The dosage may be changed during the administration period. The daily dose may be administered once or multiple times (e.g., 2 to 4 times).

[0052] The administration method is appropriately selected depending on the age, weight, health condition, etc. of the subject. The administration method may be oral or parenteral, but parenteral administration is preferred. Parenteral administration includes subcutaneous administration, intradermal administration, intramuscular administration, intraperitoneal administration, intravenous administration, intrathecal administration, intrathecal administration, brain parenchyma administration, intraventricular administration, intravitreal administration, suprachoroidal administration, or subretinal administration. The oligonucleotide is administered, for example, by injection.

[0053] In addition to the oligonucleotide, the pharmaceutical composition may contain pharmaceutically acceptable carriers or additives such as sterile water, physiological saline, stabilizers, excipients, antioxidants, buffers, preservatives, surfactants, chelating agents, and binders. The oligonucleotide may be encapsulated in a carrier such as liposomes suitable for administration of nucleic acid drugs. The dosage form may be, but is not limited to, an injection. Injections include solution injections, suspension injections, emulsion injections, and injections prepared before use (e.g., lyophilized injections). The pharmaceutical composition may be provided as a kit, and the kit may further include a buffer solution used for preparation before use, instructions for use, and the like.

[0054] The subject can be a mammal, such as a human or a non-human mammal. Non-human mammals include, for example, mice, rats, rabbits, cats, dogs, sheep, pigs, horses, cows, and monkeys. In some embodiments, the subject is a human.

[0055] In certain aspects, the present disclosure relates to a method of treating or preventing a TAU-associated disease, comprising administering to a subject an effective amount of a splice-switching oligonucleotide that binds to intron 1B of TAU pre-mRNA. In certain aspects, the present disclosure relates to a splice-switching oligonucleotide that binds to intron 1B of TAU pre-mRNA for use in treating or preventing a TAU-associated disease. In certain aspects, the present disclosure relates to the use of a splice-switching oligonucleotide that binds to intron 1B of TAU pre-mRNA for the manufacture of a medicament for treating or preventing a TAU-associated disease.

[0056] Exemplary embodiments of the present disclosure are described below. [1] A splice-switching oligonucleotide that binds to intron 1B of TAU pre-mRNA. [2] The splice-switching oligonucleotide according to 1 above, which is capable of increasing the amount of TAU mRNA containing TAU exon 1B. [3] The splice-switching oligonucleotide according to 1 or 2 above, which is capable of decreasing the amount of TAU protein. [4] The splice-switching oligonucleotide according to any one of 1 to 3 above, which comprises a sequence complementary to a portion of intron 1B of TAU pre-mRNA. [5] The splice-switching oligonucleotide according to any one of 1 to 4 above, which comprises a sequence complementary to at least a portion of positions 6 to 24 of SEQ ID NO: 2. [6] The splice-switching oligonucleotide according to any one of 1 to 5 above, comprising a sequence complementary to a sequence having 70%, 75%, 80%, 85%, 90%, or 95% or more sequence identity with the sequence of 5'-GGCAAAGAATTCAGAAATT-3' (SEQ ID NO: 3), or a sequence complementary to 5'-GGCAAAGAATTCAGAAATT-3' (SEQ ID NO: 3) or a sequence in which 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 1 or 2 bases have been modified in the sequence of SEQ ID NO: 3. [7] The splice-switching oligonucleotide according to any one of 1 to 6 above, comprising a sequence complementary to a sequence consisting of at least 13 consecutive bases in the sequence of 5'-GGCAAAGAATTCAGAAATT-3' (SEQ ID NO: 3).[8] A sequence complementary to a sequence having 70%, 75%, 80%, 85%, 90%, or 95% or more sequence identity with the sequence 5'-GGCAAAGAATTCAGAAAT-3' (SEQ ID NO: 4) or 5'-GCAAAGAATTCAGAAATT-3' (SEQ ID NO: 5); or 8. The splice-switching oligonucleotide according to any one of 1 to 7 above, comprising or consisting of a sequence complementary to the sequence 5'-GGCAAAGAATTCAGAAAT-3' (SEQ ID NO: 4) or 5'-GCAAAGAATTCAGAAATT-3' (SEQ ID NO: 5), or a sequence complementary to a sequence in which 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 1 or 2 bases have been modified in the sequence 5'-GGCAAAGAATTCAGAAAT-3' (SEQ ID NO: 4) or 5'-GCAAAGAATTCAGAAATT-3' (SEQ ID NO: 5). [9] The splice-switching oligonucleotide according to any one of 1 to 8, which comprises a sequence complementary to or consists of the sequence 5'-GGCAAAGAATTCAGAAAT-3' (SEQ ID NO: 4) or 5'-GCAAAGAATTCAGAAATT-3' (SEQ ID NO: 5).

[10] The splice-switching oligonucleotide according to any one of 1 to 9 above, which comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, or 95% or more sequence identity with the sequence of 5'-ATTTCTGAATTCTTTGCC-3' (SEQ ID NO: 6) or 5'-AATTTCTGAATTCTTTTGC-3' (SEQ ID NO: 7), or a sequence in which 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 1 or 2 bases are modified in the sequence of 5'-ATTTCTGAATTCTTTGCC-3' (SEQ ID NO: 6) or 5'-AATTTCTGAATTCTTTTGC-3' (SEQ ID NO: 7), or in the sequence of SEQ ID NO: 6 or SEQ ID NO: 7.

[11] The splice-switching oligonucleotide according to any one of 1 to 10, comprising or consisting of the sequence 5'-ATTTCTGAATTCTTTGCC-3' (SEQ ID NO: 6) or 5'-AATTTCTGAATTCTTTGC-3' (SEQ ID NO: 7).

[12] The splice-switching oligonucleotide according to any one of 1 to 11 above, which does not contain six or more, five or more, or four or more consecutive natural deoxyribonucleosides.

[13] The splice-switching oligonucleotide according to any one of 1 to 12 above, which is not an oligonucleotide consisting of a central region containing four or more, five or more, or six or more consecutive natural deoxyribonucleosides and two or more base-long regions containing at least one unnatural nucleoside at the 5'-end and 3'-end of the central region.

[14] The splice-switching oligonucleotide according to any one of 1 to 13 above, which is 16 to 20 bases long.

[15] The splice-switching oligonucleotide according to any one of 1 to 14 above, which is capable of selectively increasing the amount of TAU mRNA containing TAU exon 1B in excitatory neurons.

[16] The splice-switching oligonucleotide according to any one of 1 to 15, which is capable of increasing the amount of TAU mRNA comprising TAU exon 1B in excitatory neurons by at least 5% greater than the increase in inhibitory neurons.

[17] The splice-switching oligonucleotide according to any one of 1 to 16, which is capable of reducing the amount of TAU protein selectively in excitatory neurons.

[18] The splice-switching oligonucleotide according to any one of 1 to 17, which is capable of reducing the amount of TAU protein in excitatory neurons by at least 5% greater than the decrease in inhibitory neurons.

[19] A sequence complementary to a sequence having 70%, 75%, 80%, 85%, 90%, or 95% or more sequence identity with the sequence 5'-GGCAAAGAATTCAGAAAT-3' (SEQ ID NO: 4) or 5'-GCAAAGAATTCAGAAATT-3' (SEQ ID NO: 5); or An oligonucleotide comprising or consisting of a sequence complementary to the sequence of 5'-GGCAAAGAATTCAGAAAT-3' (SEQ ID NO: 4) or 5'-GCAAAGAATTCAGAAATT-3' (SEQ ID NO: 5), or a sequence complementary to a sequence in which 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 1 or 2 bases have been modified in the sequence of 5'-GGCAAAGAATTCAGAAAT-3' (SEQ ID NO: 4) or 5'-GCAAAGAATTCAGAAATT-3' (SEQ ID NO: 5).

[20] An oligonucleotide comprising or consisting of a sequence having 70%, 75%, 80%, 85%, 90%, or 95% or more sequence identity to the sequence of 5'-ATTTCTGAATTCTTTGCC-3' (SEQ ID NO: 6) or 5'-AATTTCTGAATTCTTTTGC-3' (SEQ ID NO: 7), or comprising or consisting of the sequence of 5'-ATTTCTGAATTCTTTGCC-3' (SEQ ID NO: 6) or 5'-AATTTCTGAATTCTTTTGC-3' (SEQ ID NO: 7), or a sequence in which 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 1 or 2 bases have been modified in the sequence of SEQ ID NO: 6 or SEQ ID NO: 7.

[21] A pharmaceutical composition comprising the splice-switching oligonucleotide according to any one of 1 to 18 above or the oligonucleotide according to 19 or 20 above.

[22] The pharmaceutical composition according to 21, for treating or preventing a TAU-related disease.

[23] The pharmaceutical composition according to 22, wherein the TAU-related disease is tauopathy or epilepsy.

[24] The pharmaceutical composition according to 22, wherein the TAU-related disease is selected from the group consisting of Alzheimer's disease, vascular dementia, dementia with Lewy bodies, Parkinson's disease, amyotrophic lateral sclerosis, Down syndrome, Pick's disease, chronic traumatic encephalopathy, progressive supranuclear palsy, basal ganglionic degeneration, and myotonic dystrophy type 1.

[25] The pharmaceutical composition according to claim 22, wherein the TAU-related disease is selected from the group consisting of Dravet syndrome, tuberous sclerosis complex, periodic ataxia, CDFE syndrome, and DEE14 or 18.

[26] The pharmaceutical composition according to claim 22, wherein the TAU-related disease is selected from the group consisting of glaucoma and age-related macular degeneration.

[27] The pharmaceutical composition according to claim 21, for suppressing neurodegeneration caused by excessive neural synchronization.

[28] A method for treating or preventing a TAU-related disease, comprising administering to a subject an effective amount of the splice-switching oligonucleotide according to any of claims 1 to 18, the oligonucleotide according to claim 19 or 20, or the pharmaceutical composition according to any of claims 21 to 27.

[29] The splice-switching oligonucleotide according to any of claims 1 to 18, or the oligonucleotide according to claim 19 or 20, for use in treating or preventing a TAU-related disease.

[30] Use of the splice-switching oligonucleotide according to any one of 1 to 18 above, or the oligonucleotide according to 19 or 20 above, for the manufacture of a medicament for treating or preventing a TAU-related disease.

[0057] 1. Synthesis and Purification of Oligonucleotides The oligonucleotides shown in Table 1 were synthesized.

[0058]

[0059] <Method> Compounds 1, 2, 3, 4, 5, 6, 7, and 8 (Table 1) were synthesized according to the procedure shown in Table 2. Using commercially available 5'-O-DMTr nucleoside CPG (1 μmol scale), steps 1 to 8 in Table 2 were repeated using an automatic nucleic acid synthesizer (M-8-MX, manufactured by Nippon Techno Service Co., Ltd.) to elongate the chain. 2 Cl 2 The 5'-O-DMTr group was removed with 3% DCA in 25% NH 3Deprotection of the nucleobase and phosphate protecting groups of compounds 7 and 8 and cleavage of the linker were achieved by treating them with 20% diethylamine in MeCN at 25°C for 1 hour, followed by treatment with a mixture of TEA-MeOH-water (1:1:2, v / v / v) at 65°C for 20 hours. The resulting crude product was purified by ion-exchange HPLC (Thermo Scientific DNAPac PA100). Fractions containing the desired oligonucleotides were pooled, purified using a simple reverse-phase column (Waters Sep-Pak), and lyophilized. The yield was determined by UV quantification at 260 nm (Shimadzu UV-1800, manufactured by Shimadzu Corporation), and the composition was identified by LC-MS (Waters Xevo G2-XS Qtof).

[0060] <Results> Compound 1: yield 1.2 mg, ESI-MS: m / z calcd 6031.6, found 6030.7. Compound 2: yield 1.1 mg, ESI-MS: m / z calcd 6006.5, found 6005.7. Compound 3: yield 0.2 mg, ESI-MS: m / z calcd 6006.5, found 6006.0. Compound 4: yield 1.0 mg, ESI-MS: m / z calcd 6016.5, found 6015.7. Compound 5: Yield 0.7 mg, ESI-MS: m / z calcd 6042.5, found 6041.7. Compound 6: Yield 1.4 mg, ESI-MS: m / z calcd 6026.5, found 6025.9. Compound 7: Yield 0.8 mg, ESI-MS: m / z calcd 6768.2, found 6768.3. Compound 8: Yield 2.6 mg, ESI-MS: m / z calcd 6775.3, found 6777.9.

[0061]

[0062] Scramble and comparative compound 1 were also synthesized in the same manner. Scramble is a negative control. Comparative compound 1 is an example of a gapmer-type antisense oligonucleotide against TAU ​​mRNA.

[0063] 2. Identification of the sense sequence that inserts exon 1B To identify SSO-type antisense oligonucleotides, cDNA derived from human iPS cell-derived neurons (hereinafter referred to as "iPS neurons") treated with compound 2, 3, 4, or 5 was subjected to RT-PCR and electrophoresis, and splice switching activity was qualitatively evaluated.

[0064] <Method> iCell GlutaNeurons 01279 (FUJIFILM Cellular Dynamics, Inc.), a product containing both glutamatergic neurons (excitatory neurons) and GABAergic neurons (inhibitory neurons), was used according to the package insert. TM Poly-D-lysine 384-well black, clear, flat-bottom, TC-treated microplates (Corning) were coated with Poly-L-ornithine (Sigma-Aldrich) and Corning® Matrigel® Basement Membrane Matrix Growth Factor Reduced (Corning). iPS cells were then suspended and seeded in Complete BrainPhys medium (absent antibiotics) at 26,000 to 30,000 cells / well, final volume 40 μL / well. The following day, an equal volume of 2 μM oligonucleotide-containing medium (double the concentration) was added to the cells to achieve a final oligonucleotide concentration of 1 μM (final volume 80 μL / well). For the oligonucleotide-free conditions, distilled water (hereinafter referred to as d.w., Otsuka Pharmaceutical Factory, Inc.) was added to a concentration of 0.1%. To change the medium, 40 μL of the culture supernatant was discarded and 40 μL of fresh medium containing 1 μM oligonucleotide was added, and this procedure was repeated every 3 days.

[0065] To recover the lysate 16 days after seeding, the entire medium was removed, and 7 μL of RIPA Buffer 1x (prepared solution, protease inhibitor-free, Nacalai Tesque) was added. After stirring, the cells were solubilized by freeze-thawing (RIPA lysate). Next, cDNA was synthesized using the following procedure. Referring to the package insert for the SuperPrep® II Cell Lysis & RT Kit for qPCR (TOYOBO), 9 μL of lysis buffer (a mixture of 8.75 μL of Lysis Solution, 0.2 μL of RNase Inhibitor, and 0.05 μL of gDNA Remover) was mixed with 1 μL of RIPA lysate, and the mixture was left to stand at room temperature for 5 minutes to decompose the genomic DNA and obtain an RNA-containing solution. Next, for reverse transcription, 5X RT Master Mix, the RNA-containing solution, and dw were mixed and reacted at 37°C (15 minutes), 50°C (5 minutes), and 98°C (5 minutes) to obtain a cDNA solution, which was then diluted 10-fold with dw.

[0066] To perform PCR, a TAU primer was diluted with dw to a final concentration of 200 nM or a β-actin (ACTB) primer was diluted with dw to a final concentration of 100 nM and added to PrimeSTAR® GXL Premix (TAKARA). The following primers were synthesized and used (Integrated DNA Technologies, Inc. / IDT). <For detecting TAU mRNA> 118 (118-Fw-Mapt-Exon1) (5'-CATGCACCAAGACCAAGAGG-3') (SEQ ID NO: 18), 120 (120-Rv-Mapt-Exon4) (5'-TCACGTGACCAGCAGCTTC-3') (SEQ ID NO: 19) <For detecting ACTB mRNA> Primers included in IDT Hs. PT. 39a. 22214847: (5'-ACAGAGCCTCGCCTTTG-3') (SEQ ID NO: 20), (5'-CCTTGCACATGCCGGAG-3') (SEQ ID NO: 21)

[0067] The synthetic template DNAs for the RT-PCR positive controls were synthesized with the following sequences (gBLOCKS, IDT). 110-TAU nonproductive mRNA (DNA-standard) (E1B-E4): Contains the sequence of exon 1B between exon 1 and exon 4. 110 (5'-TCAGGGGGGGCTACACCATGCACCAAGACCAAGAGGGTGACACGGACGCTGGCCTGAAAGAGGGGAGTGAATTCACTGAGCTGAGAGCTGAGGAACCATTGATCTGATGGCTGAGACACCACTGGGAAGACTG GAGAGGCTTTTCTGGGCATGCAGTGCCAGGCACAGGAGGAGCTGAGGGAAGATGACTAAGAGCTGAAGAAGCAGGCATTGGAGACACCCCCCAGCCTGGAAGACGAAGCTGCTGGTCACGTGACCCAA-3') (SEQ ID NO: 22) 111-TAU productive mRNA (DNA-standard) (E1-E4): Has a sequence that corresponds to exon 4 next to exon 1.111 (5'-TCAGGGGGGCTACACCATGCACCAAAGACCAAAGAGGGTGACACGGACGCTGGCCTGAAAGCTGAAG AAGCAGGCATTGGAGACACCCCAGCCTGGAAGACGAAGCTGCTGGTCACGTGACCCAAG-3') (SEQ ID NO: 23) ACTB(5'-GCATCGACATCGACTAACCGCCGAGACCGCGTCCGCCCCGCGAGCAGAGCCTCGCCTTTGCCGATCCGCCGCCCGTCCACACCCGC CGCCAGCTCACCATGGATGATGATATCGCCGCGCTCGTCGTCGACAACGGCTCCGGCATGTGCAAGGCCGGCTTCGCGGGCGACGATGCCCCCCGGG CCGTCTTCCCCTCCATCGTGGGGCGCCCCAGGCACCAGGGGCGTGATGGTGGGCATGGGTCAGAAGGATTCCTATGTGGGCGACGAGGCCCAGAGCAA GAGAGGCATCCTCACCCTGAAGTACCCCATCGAGCACGGCATCGTCACCAACTGGGACGACATGGAGAAATCTGGCACCACAC-3') (SEQ ID NO: 24).

[0068] Touchdown PCR was performed using a GeneAmp PCR System 9700 (Applied Biosystems) thermal cycler, with three cycles of denaturation at 98°C (10 seconds); 66°C (15 seconds); 68°C (15 seconds), followed by three cycles of denaturation at 98°C (10 seconds); 64°C (15 seconds); 68°C (15 seconds), followed by 10 cycles of denaturation at 98°C (10 seconds); 62°C (15 seconds); 68°C (15 seconds), and finally 40 cycles of denaturation at 98°C (10 seconds); 60°C (15 seconds); 68°C (15 seconds). 5 μL of PCR amplification product was mixed with 1 μL of Gel Loading Dye, Purple (6X) (New England Biolabs Japan, Inc.), and electrophoresed on 3% agarose 21 (for low molecular weight nucleic acid isolation) (Fujifilm Wako Pure Chemical Industries, Ltd.) and TAE (Nippon Gene). 100 bp DNA Ladder One (Nacalai Tesque) was used as a marker. To detect bands, SYBR 10000-fold diluted with TAE was used.TM The gel was stained with Gold Nucleic Acid Gel Stain (10,000X Concentrate in DMSO) (Thermo Fisher Scientific) under light protection and transferred to Amersham. TM ImageQuant TM Visualization was performed using fluorescence (Cy2) from an 800 series (IQ800) (Global Life Science Technologies Japan, Inc.).

[0069] <Results> The 135 nucleotides (nt) previously recognized as an intron were registered as an exon under ENST00000571311.5. The 135 nucleotides (nt) were inserted between exon 1 and exon 2 (Figure 1A). Hereafter, this 135-nt exon will be referred to as exon 1B. Because the insertion of exon 1B results in the appearance of a premature termination codon, this transcript is assumed to degrade via nonsense-mediated mRNA decay (NMD), and therefore will be referred to as nonproductive mRNA. Three variants of the N-terminal region of human productive mRNA, which is the basis of TAU protein, have been reported: "1N TAU," which contains exon 2 but not exon 3; "2N TAU," which contains both exons 2 and 3; and "0N TAU," which contains neither exon 2 nor 3 (Wang JZ et al., Prog Neurobiol. 85. 148-75. 2008, Figure 5). Based on this, three patterns of nonproductive mRNA containing exon 1B are conceivable. However, in this study, two patterns of nonproductive mRNA expression were primarily detected in iPS neurons by RT-PCR. Therefore, Figure 1A shows only the transcripts actually detected in this study.

[0070] To identify the sense sequence in the pre-mRNA that increases nonproductive mRNA by forcing exon 1B insertion using SSO, we evaluated TAU mRNA variants (transcripts) by introducing an 18-nt oligonucleotide into iPS neurons at 1 μM without the use of a transfection reagent (freeuptake). To identify the transcripts, we designed a forward primer (118) for exon 1 and a reverse primer (120) for exon 4, and evaluated the molecular weight differences of the RT-PCR products. As a result, in the untreated control, bands were detected at approximately 100 bp (base pair) and approximately 200 bp (Figure 1B, top). The band observed at approximately 100 bp was detected at the same molecular weight as the 0N TAU positive control template synthetic DNA, suggesting that it represents productive mRNA in which exon 4 follows exon 1. The band observed at approximately 200 bp was considered to correspond to the molecular weight of 1N TAU. Next, when oligonucleotides were added, new bands were detected with compounds 3 and 4, each consisting of the aforementioned approximately 100 bp and approximately 200 bp bands plus a 135 bp band (Figure 1B, top). The approximately 235 bp band was considered to correspond to nonproductive mRNA, since it had the same molecular weight as the positive control template synthetic DNA, in which a 135 bp exon 1B fragment was inserted into a 104 bp 0N Tau fragment. The band observed at approximately 335 bp was considered to correspond to nonproductive mRNA, in which a 135 bp fragment was inserted into a 191 bp 1N TAU fragment. The presence of cDNA other than TAU was confirmed using β-actin as a loading control (Figure 1B, bottom).

[0071] 3. Confirmation of exon structure by Sanger sequencing To investigate the exon-exon junction into which the 135-nt exon 1B was inserted, the approximately 235 bp and approximately 335 bp bands observed in the compound 4-treated sample were excised, cloned, and then subjected to Sanger sequencing.

[0072] <Method> cDNA derived from the compound 4-treated sample obtained in Experiment 2 was subjected to PCR using primers 118 and 120, followed by electrophoresis. Bands around 335 bp, 235 bp, and 200 bp were excised from the gel and purified using a GEL / PCR Purification Mini Kit (FAVORGEN) according to the manufacturer's instructions. To add dA using 10x A-attachment Mix (TOYOBO), 0.5 μL of 10x A-attachment Mix was added to 4.5 μL of the purified sample, and the mixture was incubated at 60°C for 30 minutes. To clone into pT7Blue T-vector (Novagen), 2 μL of the sample was added to 0.5 μL of pT7Blue T-vector and mixed, and 2.5 μL of DNA Ligation Kit <Mighty Mix> (TAKARA) was added and reacted for 30 minutes at 16°C. The entire solution was transformed into prepared competent cells (Escherichia coli JM109 strain) by heat treatment (42°C, 30 seconds), and the cells were plated on ampicillin-containing LB agar medium plates (Unitech Co., Ltd., Cat. No. LBA-Op) supplemented with X-gal and IPTG. After overnight incubation at 37°C, white or light blue colonies were picked and cultured in 100 μL of ampicillin-containing LB medium (final concentration 100 μg / mL, Unitech Co., Ltd.). 2 μL of the LB medium that had begun to suspend was mixed with PrimeSTAR GXL DNA Polymerase (TAKARA) and primers (final concentration 0.2 or 0.3 μM) to prepare a PCR reaction solution (reaction scale: 15 μL). The following primers were used: pT7Blue-F-m13r (5'-CAGGCTTTACACTTTATGCTTCC-3') (SEQ ID NO: 25); pT7Blue-R2-u19 (5'-CGATTTCGGCCTATTGGTTA-3') (SEQ ID NO: 26). PCR was performed using a GeneAmp PCR System 9700 (Applied Biosystems) thermal cycler, with 30 cycles of denaturation at 98°C (10 seconds), 60°C (15 seconds), and 68°C (30 seconds). Colony PCR samples (5 μL) from each clone were electrophoresed on a 2% agarose gel to confirm band sizes.The selected clones were cultured in 1 mL of ampicillin-containing LB medium, and the plasmid was extracted using the standard alkaline SDS method. For sequencing analysis, the purified plasmid (template) was sequenced using either of the above primers (pT7Blue-F-m13r or pT7Blue-R2-u19) in a paired-end fashion using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems). The sequencing reaction was performed for 25 cycles [denaturation: 96°C (10 seconds); 50°C (5 seconds); 60°C (2 minutes)]. The measurements were performed using an ABI PRISM 3130x1 Genetic Analyzer (Applied Biosystems).

[0073] <Results> The band around 335 bp observed by RT-PCR from the compound 4-treated sample was excised, purified, and then cloned into a plasmid (Figure 2A, top, 24 clones). Two clones (numbers 2 and 10) contained the desired band with an approximately 335 bp insert at around 750 bp, while three clones (numbers 6, 7, and 11) contained a band (450 bp) corresponding to the plasmid without any insert. Sanger sequencing of clone 2 revealed that exon 1 was followed by a 135-nt exon 1B, followed by an 87-nt exon 2, followed by exon 4, as shown in the electropherogram in Figure 2B. The band around 235 bp observed by RT-PCR from the compound 4-treated sample was also analyzed in the same manner (Figure 2A, middle, 16 clones). Of the 16 clones, clone 10 (approximately 700 bp) was assumed to contain the approximately 235 bp PCR product of interest. Sanger sequencing revealed that exon 1B (135 nt) was located next to exon 1B, followed by exon 4, as shown in Figure 2C. Finally, the band around 200 bp observed in RT-PCR from the compound 4-treated sample was also analyzed in the same manner (Figure 2A, bottom, 24 clones). Sanger sequencing of clone 24, assumed to contain the approximately 200 bp PCR product of interest, revealed that exon 1 was followed by exon 2, followed by exon 4, as shown in Figure 2D. While the above analysis was performed using a single-end sequence from the forward primer side, the same sequence was also confirmed using paired-end analysis from the reverse primer side (data not shown).

[0074] 4. Construction of a qPCR system for selectively quantifying TAU productive and nonproductive mRNAs. Using synthetic DNA corresponding to "TAU nonproductive mRNA" in which a 135-nt exon 1B fragment is inserted between exons 1 and 4, or "TAU productive mRNA" in which exons 1 and 4 are connected, we confirmed that the designed primers and probes functioned in qPCR.

[0075] <Method> As synthetic template DNAs, 110-TAU and 111-TAU described in <Method> of Experiment 2, and the following 117-TAU were synthesized (gBLOCKS, IDT). Hereinafter, 110-TAU, 111-TAU, and 117-TAU may be simply referred to as 110, 111, and 117, respectively. 117-TAU pre-mRNA (DNA-standard) (I3-E4): Has a sequence that follows intron 3 and then exon 4. 117 (5'-tctagtaaacaataactgtcttgcttttacccccccttcatttgctgacacatacaccagCTGAAG AAGCAGGCATTGGAGACACCCCAGCCTGGAAGACGAAGCTGCTGGTCACGTGACCCAAG-3') (SEQ ID NO: 27).

[0076] For qPCR, a PCR reaction solution containing synthetic template DNA (110, 111, or 117), THUNDERBIRD® PROBE qPCR MIX (TOYOBO), qPCR probe (final concentration 0.15 μM), and primers (final concentration 0.4 μM) was prepared according to the package insert (15 μL of PCR reaction solution). To accurately evaluate PCR amplification efficiency and quantify copy number as an absolute value, known copy numbers of 110, 111, or 117 were serially diluted with yeast RNA-containing d.w. (final concentration 10 μg / mL, Invitrogen) and a standard curve was created using the resulting Ct values. The copy number (X axis) and the resulting Ct (Y axis) were plotted on a graph (Figures 3A, 3B, and 3C, bottom). Graphs were created using GraphPad PRISM version 6.07. qPCR was performed using a ViiA7 (Applied Biosystems) with initial denaturation at 95°C (1 minute), followed by 40 cycles of 95°C (15 seconds), 60°C (45 seconds). The primers and probes used were as follows: <For detecting TAU nonproductive mRNA> 112 (Fw-Mapt-Exon1B-4) (5'-AGGGAAGATGACTAAGAGCTGA-3') (SEQ ID NO: 28) 114 (Rv-Mapt-Exon4) (5'-TCACGTGACCAGCAGCTT-3') (SEQ ID NO: 29) 113 (Probe-Mapt-Exon4) (5'- / 56-FAM / AGACACCCC / ZEN / CAGCCTGGAAGA / 3IABkFQ / -3') (SEQ ID NO: 30) <For detecting TAU productive mRNA> 115 (Fw-Mapt-Exon1-4) (5'-GCTGGCCTGAAAGCTGA-3') (SEQ ID NO: 31) 114 (see above) 113 (see above) <For detecting TAU pre-mRNA> 116 (Fw-Mapt-Intron3) (5'-CTTCATTTGCTGACACATACACC-3') (SEQ ID NO: 32) 114 (see above) 113 (see above)

[0077] <Results> We constructed an absolute quantification system for highly expressed TAU productive mRNA, in which exon 4 is linked next to exon 1, and TAU nonproductive mRNA, in which exon 1B is inserted. First, as shown in Figure 3A, qPCR was performed using a TAU nonproductive mRNA detection kit containing forward primer 112, designed to span the region between exon 1B and exon 4. Ct values ​​were not calculated by the 40th cycle for synthetic template DNA 111, which corresponds to productive mRNA in which exon 1 and exon 4 are linked but not exon 1B, and synthetic template DNA 117, which corresponds to pre-mRNA containing intron 3. However, Ct values ​​were calculated according to the copy number for synthetic template DNA 110, which corresponds to nonproductive mRNA in which exon 4 is linked next to exon 1B. Furthermore, under these conditions, a correlation was found between the Ct value and the copy number of the template DNA, and it was revealed that the number of copies of cDNA contained in the reaction solution could be calculated from the Ct value of the sample to be measured. The PCR amplification efficiency was calculated from the slope of the curve and was found to be 94.4%, which was quantifiable from the minimum test concentration of 5 copies / well.

[0078] Next, to quantify TAU productive mRNA, qPCR was performed using a TAU productive mRNA detection kit containing forward primer 115, designed to span exons 1 and 4, as shown in Figure 3B. Ct values ​​were calculated down to low copy numbers for primer 111, corresponding to productive mRNA. Meanwhile, for primer 110, corresponding to nonproductive mRNA, only the highest DNA copy number tested (500,000 copies / well) was detected with a Ct value of 35.8, indicating very little cross-reactivity. However, this was considered to be more than 100,000-fold selective for the productive mRNA of interest. The PCR amplification efficiency was 91.3%, and quantification was possible from the lowest tested concentration of 5 copies / well.

[0079] Furthermore, as shown in Figure 3C, when qPCR was performed using a TAU pre-mRNA detection kit containing forward primer 116 designed within intron 3, a Ct value was calculated only for template synthetic DNA 117 corresponding to pre-mRNA. The PCR amplification efficiency was 98.7%, and quantification was possible at the minimum concentration tested, 5 copies / well.

[0080] As described above, under the qPCR conditions of Experiment 4, a system capable of selectively detecting and quantifying productive and nonproductive mRNAs of TAU transcripts was constructed.

[0081] 5. Examination of splice switching activity of oligonucleotides To examine the splice switching activity, productive and nonproductive mRNAs were quantified by qPCR.

[0082] <Method> Six oligonucleotides (compounds 1, 2, 3, 4, 5, and 6) (Figure 4A) (3 μM, N = 2 wells, 2 biological replicates) were treated with freeuptake in the iPS neuron culture method described in Experiment 2 (15 days of treatment), followed by preparation of cDNA samples. Untreated samples were treated with d.w. to a final concentration of 0.1% (N = 6 wells). Next, the amount of TAU cDNA in the iPS neuron samples was quantified using the qPCR method described in Experiment 4. The TAU quantification value was normalized by the ACTB quantification value. Ready-made ACTB primers and probes (Hs. PT. 39a. 22214847 (IDT)) were used. Primer 1 (5'-ACAGAGCCTCGCCTTTG-3') (SEQ ID NO: 20) Primer 2 (5'-CCTTGCACATGCCGGAG-3') (SEQ ID NO: 21) Probe (5'- / 56-FAM / TCATCCATG / ZEN / GTGAGCTGGCGG / 3IABkFQ / -3') (SEQ ID NO: 33) The synthetic template DNA for the ACTB standard curve was SEQ ID NO: 24 described in the method of Experiment 2. The graph was prepared by correcting the untreated sample to 100%.

[0083] <Results> In this experiment, the changes in nonproductive and productive mRNA levels when each oligonucleotide was used were quantified by qPCR. Compounds 3 and 4 increased nonproductive mRNA by 2.9-fold and 2.3-fold, respectively (Figure 4B, left). Meanwhile, productive mRNA levels were reduced by 28% and 38%, respectively (Figure 4B, right). These results demonstrate that compounds 3 and 4 can regulate TAU splicing. Comparative gapmer-type compound 1, used as a positive control with a different mechanism of action, reduced nonproductive and productive mRNA levels by 82% and 81%, respectively, confirming that comparative compound 1 reduces TAU levels through a mechanism other than splice switching.

[0084] 6. Absolute quantification of TAU protein A system was constructed to equally quantify the six variants of TAU protein.

[0085] <Method> To quantify TAU protein, a homogeneous time resolved fluorescence (HTRF®) assay (64NTAUPEG, Cisbio / PerkinElmer Japan) was used. The assay was performed as follows, with reference to the attached instructions. Tau 441 (2N4R) (SP-495-100) and Tau 352 (0N3R) (SP-497-100) recombinant TAU ​​proteins (R&D Systems) were serially diluted in 1X RIPA buffer. 0.1 μL of Total-Tau Eu Cryptate Antibody solution was added to 1.9 μL of detection buffer (Solution A). Next, 0.1 μL of Total-Tau d2 Antibody solution was added to 1.9 μL of detection buffer (Solution B). A 4 μL antibody solution, consisting of 2 μL each of Solution A and Solution B, was added to the 16 μL of TAU recombinant protein (Microplate, 384 well, PS, F-bottom, small volume, hibase, medium binding, white, Greiner Bio-One). The plate was incubated overnight at 23-25°C in the dark. Fluorescence signals were measured at 620 nm and 665 nm (detection filters) using an HTRF® microplate reader (ARTEMIS) with excitation at 320 nm. The detected value at 665 nm was divided by the detected value at 620 nm and multiplied by 10,000, and the resulting value was plotted on the vertical axis (N = 2 wells). The molar concentration calculated from the molecular weight of the recombinant protein and the total number of amino acids was plotted on the horizontal axis. Graphs were created using GraphPad PRISM version 6.07.

[0086] <Results> Because there are six splicing variants of TAU productive mRNA in the central nervous system (Wang JZ et al., Prog Neurobiol. 85. 148-75. 2008), it is thought that six types of TAU protein with different molecular weights are expressed (Figure 5, top). In this experiment, we evaluated whether the HTRF® kit commercially available from Cisbio / PerkinElmer Japan, whose anti-TAU antibody details are not disclosed, recognizes all TAU proteins equally. When the TAU recombinant protein derived from the longest TAU ​​product mRNA (2N4R TAU / 441 a.a.) and the TAU recombinant protein derived from the shortest TAU ​​product mRNA (0N3R TAU / 352 a.a.) were measured at varying concentrations, they were detected equally well (Figure 5, bottom).

[0087] 7. Concentration-Dependent Test I Concentration-dependent tests of oligonucleotides were carried out to quantify productive and nonproductive mRNA and TAU protein, and to examine splice-switching activity and knockdown activity of TAU protein.

[0088] <Method> In the iPS neuron culture method of Experiment 2, SSO Compound 7 (same sequence as Compound 3) or Compound 8 (same sequence as Compound 4), or gapmer-type oligonucleotide Comparative Compound 1, were treated with freeuptake (15 days of treatment) and then solubilized in RIPA Buffer 1x prepared solution without protease inhibitors. Reverse transcriptase was added and reacted to prepare cDNA samples. Untreated samples were treated with d.w. to a final concentration of 0.1%. Next, the amounts of TAU and ACTB cDNA were quantified using the qPCR method described in Experiment 4. Only the values ​​from wells where the quantified ACTB value fell within the "mean value of all measurements ± 2 times the standard deviation" were analyzed. Neurofilament light polypeptide (NfL) was quantified as a control. The following primers and probes for NfL, and template synthetic DNA for the standard curve were used (IDT). The quantitative values ​​of TAU and NfL were corrected by the quantitative value of ACTB. The untreated values ​​were plotted on the graph as 100%. <For detecting NfL mRNA> Primer (5'-CCATCAGCAACGACCTCAA-3') (SEQ ID NO: 34) Primer (5'-GCTTCCAGGACCTTGTTCT-3') (SEQ ID NO: 35) Probe (5'- / 56-FAM / CTTCGCCAG / ZEN / CTTCATCGAGCG / 3IABkFQ / -3') (SEQ ID NO: 36) NfL(5'-CGACCTGAGCCAGGTAGCCGCCATCAGCAACGACCTCCAAGTCCATCCGCACGCAGGAGAAGGCGCAGCTCCAGGACCTCCAATGACCGCTTCG CCAGCTTCATCGAGCGCGTGCACGAGCTGGAGCAGCAGAACAAGGTCCTGGAAGCCGAGCTGCTGGTGCTGCGCCAGAAGCACTCC-3') (SEQ ID NO: 37).

[0089] Next, to measure total protein content using a BCA kit (Nacalai Tesque), 2 μL of lysate solubilized in RIPA Buffer 1x (prepared solution, no protease inhibitors) was mixed with 8 μL of d.w., followed by the addition of 200 μL of BCA solution (4 μL of solution B and 196 μL of solution A) and incubation at 60°C for approximately 30 minutes. A standard curve for total protein was prepared using a BSA solution serially diluted from 500 ng / mL using the Quick Start Bovine Serum Albumin Standard Set (BIO-RAD). The absorbance at 562 nm was measured to quantify the total protein content of the lysate. Next, to measure the TAU protein concentration using the HTRF® assay, lysates solubilized in RIPA Buffer 1X (prepared solution, no protease inhibitors) were diluted 40-fold with 1X RIPA buffer containing protease inhibitor cocktail (Nacalai Tesque) to prepare a solution that could be added at 15 μL / well, and 4 μL / well of antibody solution (an equal mixture of Solution A and Solution B described in the method of Experiment 6) was mixed. For the TAU protein calibration curve, Tau 441 (2N4R) (SP-495-100, R&D Systems) serially diluted with RIPA buffer was used. The reaction was allowed to proceed overnight at 23-25°C in the dark. Fluorescence signals were measured at 620 nm and 665 nm (detection filters) using an HTRF® microplate reader (ARTEMIS) with excitation at 320 nm. The detected value at 665 nm was divided by the detected value at 620 nm and multiplied by 10,000 to calculate the TAU protein concentration in iPS neuron-derived lysates using a Tau 441 (2N4R) calibration curve. The TAU protein quantification value was then divided by the total protein quantification value using BCA, corrected to 100% for untreated cells, and plotted on a graph. Graphs were created using GraphPad PRISM version 6.07.

[0090] <Results> Concentration dependency was evaluated using Compound 7 (same sequence as Compound 3) and Compound 8 (same sequence as Compound 4), which had modified oligonucleotide modifications. TAU nonproductive mRNA increased at concentrations on the order of several nM, and TAU productive mRNA decreased at concentrations of approximately 10 nM (Figures 6A and 6B). Furthermore, Compounds 7 and 8 reduced the amount of TAU protein (Figures 6A and 6B). On the other hand, the gapmer-type comparative compound 1 reduced both nonproductive and productive mRNA at concentrations on the order of nM (Figure 6C). Since no reduction in NfL was observed with any of the oligonucleotides, Compounds 7 and 8 may be able to selectively reduce TAU productive mRNA.

[0091] 8. Identification of neurons in which TAU nonproductive mRNA is increased Cells affected by SSO were identified by cell staining.

[0092] <Method> In the iPS neuron culture method of Experiment 2, SSO Compound 7 (N = 2 wells) or Compound 8 (N = 2 wells) was treated with freeuptake (15 days of treatment), followed by fixation in 10% neutral buffered formalin for approximately 16 hours at room temperature. However, to reduce cell detachment during fixation, the coating agent was changed from Poly-L-ornithine (Sigma-Aldrich) to 0.1% polyethyleneimine solution. In addition, to increase the proportion of inhibitory neuron populations, iCell® GABAergic neurons (FUJIFILM Cellular Dynamics, Inc.) and iCell GlutaNeurons 01279 were mixed at a ratio of approximately 20:80 and seeded. Target Probe-BA-Hs-MAPT-211-2EJ-O1-C1 (1201211-C1) and BaseScope were purchased from Advanced Cell Diagnostics, Inc. (ACD). TMTAU nonproductive mRNA was visualized with reference to the package insert for Reagent Kit v2-RED (323900). Specifically, fixed cells were washed with D-PBS(-) (PBS, Fujifilm Wako Pure Chemical Industries, Ltd.) and then digested with Protease Plus diluted 15-fold with PBS for 10 minutes at room temperature. Next, after washing with PBS, the probe was incubated at 40°C for 2 hours. After washing twice with 1x wash buffer, the AMP1 reagent was incubated at 40°C for 15-30 minutes. This procedure was repeated with AMP2, 3, 4, 5, and 6. Subsequently, after washing twice with 1x wash buffer, the AMP7 reagent was incubated at room temperature for 15-30 minutes. This procedure was then repeated with AMP8. After washing twice with 1× wash buffer, the coloring reagent BaseScope TM Fast RED-B containing BaseScope TM The Fast RED solution (a solution obtained by diluting solution B 60 times with solution A) was reacted at room temperature for approximately 30 minutes, and after washing with PBS, the plate was stored at 4°C in the dark.

[0093] Next, the following procedure was carried out to immunostain the cells with antibodies. After washing with PBS, the cells were permeabilized with a PBS solution containing 0.1% Triton X-100 at room temperature for 10 minutes. After washing with PBS, the cells were permeabilized with a Pierce TMThe sections were blocked with Protein-Free T20 (TBS) Blocking Buffer (Thermo Fisher Scientific) for 1 hour at room temperature. After washing with PBS, they were reacted with anti-neuronal nuclei antigen (NeuN) antibody (ab104224, Abcam) diluted 1,000-fold with the blocking agent and anti-gamma-aminobutylic acid (GABA) antibody (A2052-100UL, Sigma-Aldrich) diluted 1,000-fold at room temperature for 1 hour. After washing with PBS, the sections were reacted with secondary antibodies Donkey Anti-Mouse IgG H&L (Alexa Fluor® 488) (ab150105, Abcam) diluted 1,000-fold with a blocking agent, Donkey Anti-Rabbit IgG H&L (Alexa Fluor® 647) (ab150075, Abcam) diluted 1,000-fold, and DAPI (Dojindo Laboratories) diluted 10,000-fold at room temperature for 1 hour. After washing with PBS, the cells were excited at 405 nm, 488 nm, 561 nm, and 640 nm using a high-throughput cell function screening system, CellVoyager CV8000 (YOKOGAWA), and signals were detected using bandpass filters of 445 / 45 nm, 525 / 50 nm, 600 / 37 nm, and 676 / 29 nm (signals derived from DAPI, NeuN, TAU nonproductive mRNA, and GABA, respectively). Images were output using the high-content analysis software CellPathfinder.

[0094] <Results> To create probes for detecting TAU nonproductive mRNA, probes complementary to the junction between exon 1 and exon 1B and the junction between exon 1B and exon 4 were synthesized by ACD (Figure 7A, top). TAU nonproductive mRNA (Figure 7A, bottom), NeuN protein, and GABA (Figure 7B) were visualized by fluorescent staining. Compounds 7 and 8 increased the number of cells with TAU nonproductive mRNA compared with untreated controls (Figure 7A, bottom). Cells with TAU nonproductive mRNA were primarily NeuN-positive and GABA-negative (Figure 7B), indicating a tendency for TAU nonproductive mRNA to increase in excitatory neurons.

[0095] 9. Single cell RNA-seq We divided neurons into excitatory and inhibitory neurons and performed single cell RNA sequencing (scRNA-seq) to confirm the changes in TAU (MAPT) expression due to SSO.

[0096] <Method> In the iPS neuron culture method of Experiment 2, 3 μM Compound 7, Compound 8, and Comparative Compound 1 were treated with freeuptake (17 days of treatment), and then neurons were dispersed and collected using a Pain Dissociation System (Worthington Biochemical Corporation). To increase the proportion of inhibitory neuron populations, iCell® GABAergic neurons (FUJIFILM Cellular Dynamics, Inc.) and iCell GlutaNeurons 01279 were mixed and seeded. Corning® BioCoat® Poly-D-Lysine 96-well clear flat-bottom TC-treated microplates (Corning) were used, and 130,000 GlutaNeuron cells / well and 42,900 GABAergic neurons were seeded. Cultures were performed in 200 μL / well of medium, with half the medium replaced every three days. On the 18th day of culture, a digestion solution consisting of papain (vial 2), Accumax, and DNase was added to the neurons, and the cells were incubated at 37°C and 5% CO for 30 minutes. 2The cells were dispersed in the lower well. The wells were washed with the resuspension solution (HBSS containing DNase, vial 4, and 5 μM Y-27632), and the collected cell suspension was centrifuged at 500 × g for 5 minutes using a PluriStrainer-Mini 40 μm (PluriSelect USA) to remove debris. The supernatant was removed, and the precipitated cells were suspended in the resuspension solution. Five volumes of vial 4 were added to the lower well, and the mixture was centrifuged at 500 × g for 5 minutes. The supernatant was removed, and the precipitated cells were suspended in PBS containing 0.04% BSA (Miltenyi Biotec). After centrifugation at 500 × g for 5 minutes, the supernatant was removed, and the precipitated cells were resuspended in PBS containing 0.04% BSA. Viable cells were counted. Next GEM Single Cell 3′ GEM Kit v3.1, Next GEM Single Cell 3′ Library Kit v3.1, and Single Index Kit T Set A (10x Genomics) were used to prepare a suspension with 10,000 live cells / reaction in a Chromium controller (10x Genomics) according to the Chromium Single Cell 3′ Reagent Kits User Guide (v3.1 Chemistry Dual Index, 10x Genomics). The reverse transcription reaction was performed in a volume of 50 μL per well at 37°C (15 minutes), 53°C (45 minutes), and 85°C (5 minutes) to obtain a cDNA solution (C1000 Touch Thermal Cycler, Bio-Rad Laboratories, Inc.). The PCR reactions for amplifying the cDNA and GEX libraries were performed 11 and 14 times, respectively. The quality and fragment size of both libraries were measured using a High Sensitivity D5000 ScreenTape (Agilent) and a TapeStation (Agilent). The DNBSEQ-G400 sequencing system (MGI Tech) was used to measure read lengths of 28 bp for R1 and 100 bp for R2. Over 400 million reads per sample were quality assessed using FastQC (v. 0.11.9).Sequencing data was processed using Cellranger 7.0.1 and read mapping was performed using default parameters and the GRCh38 reference genome. The count matrix calculated using Cellranger was analyzed using the Seurat package (version 3.1.4) in R (version 3.6.1). The proportion of mitochondrial genes among the RNA molecules detected in each cell was calculated. Cells with a detected RNA molecule count greater than 2,500 and a proportion of mitochondrial genes less than 10% were extracted to remove cells with particularly low gene expression measurement quality. Next, expression normalization was performed, and data from four samples (untreated group, compound 7-treated group, compound 8-treated group, and comparative compound 1-treated group) was combined. 2,000 genes with large variance in expression levels were extracted from the combined data, and expression levels were normalized. Principal component analysis (PCA) was performed using 2,000 standardized genes, and the top 30 components were used for dimensionality reduction and clustering using Uniform Manifold Approximation and Projection (UMAP). Clusters with low gene expression measurement quality were identified and removed based on the number of genes detected per cluster. The excitatory neuron cluster was estimated from the SLC17A6 expression pattern. The inhibitory neuron cluster was estimated from the GAD1 and GAD2 expression patterns. Genes specific to each cluster were also extracted. Cells were classified into excitatory neurons, inhibitory neurons, ISL1-high expressing cells, and LHX8-high expressing cells. The average gene expression level for each classification was calculated, and the expression levels of SLC17A6, TBR1, GAD1, GAD2, ISL1, PCDH11Y, LHX8, and CRABP1 were plotted as a heat map. A population estimated to be excitatory neurons was extracted, and the expression levels of TAU (MAPT) in the untreated group and the oligonucleotide-treated group were compared. A population estimated to be inhibitory neurons was extracted, and the expression levels of TAU (MAPT) in the untreated group and the oligonucleotide-treated group were compared. The difference in the rate of reduction in TAU (MAPT) expression levels between excitatory neurons and inhibitory neurons in each oligonucleotide-treated group was calculated. 100 cells were randomly extracted, allowing overlap, for the TAU expression levels in the untreated group and the oligonucleotide-treated group, and the difference between the cells was determined.This experiment was repeated 10 times according to the bootstrap method, and the mean value and 95% confidence interval were calculated using SAS Software for Windows, Release 9.4 (SAS Institute Japan Ltd.).

[0097] Results: Changes in TAU expression in excitatory and inhibitory neuron populations were assessed using scRNA-seq (Figure 8A). Figure 8B shows the results of two-dimensional clustering performed by dimensional reduction of the gene expression profiles of each cell. We defined the left group (encircled group) as an excitatory neuron population based on the expression of SLC17A6 / VGLUT2, a transporter that transports glutamate into cells (Figures 8B and 8C). The bottom right group (encircled group) was defined as an inhibitory neuron based on the expression of GAD1 and GAD2, enzymes involved in GABA production (Figures 8B and 8C). The mean change in TAU (MAPT) expression (knockdown (KD) level) in the excitatory neuron population was calculated, and the comparative compound 1 treatment resulted in a 54.2% decrease compared to the untreated group (Figure 8D, far left). Next, the KD level in the inhibitory neuron population was calculated, and comparative compound 1 reduced it by 49.4% compared to the untreated group (Figure 8D, second from the left). Therefore, the difference in KD levels between both populations for comparative compound 1 was 4.8% (4.8% = 54.2% - 49.4%). Compound 7 reduced TAU by 20.4% in the excitatory neuron population and by 6.4% in the inhibitory neuron population. Therefore, the difference in KD levels between both populations for compound 7 was 14.0%, which was greater than that for comparative compound 1 (14.0% = 20.4% - 6.4%) (Figure 8D, third and fourth from the left). Compound 8 reduced TAU by 29.0% in the excitatory neuron population and by 18.2% in the inhibitory neuron population. From this, the difference in KD levels between both populations for compound 8 was 10.8%, which was larger than that of comparative compound 1 (10.8% = 29.0% - 18.2%) (Figure 8D, fifth and sixth from the left). From the above, it was found that the difference in KD levels between both populations was larger for compounds 7 and 8 than for comparative compound 1, and the decrease in TAU was stronger in the excitatory neuron population than in the inhibitory neuron population. Next, 100 cells were randomly extracted from each of the untreated and oligonucleotide-treated groups, and the difference in KD levels was determined. This experiment was repeated 10 times according to the bootstrap method, and the average values ​​and 95% confidence intervals were calculated. A statistically significant difference (significance level 5%) was confirmed between comparative compound 1 and compounds 7 and 8 (Figure 8E).From the above, it was revealed that Compounds 7 and 8 significantly and selectively reduced TAU in the excitatory neuron population compared to Comparative Compound 1.

[0098] 10. Suppression of excessive synchronization of neural activity by reduction of endogenous TAU protein We evaluated whether reduction of endogenous TAU protein by SSO suppresses excessive synchronization of neural activity.

[0099] <Method> Maestro Pro multielectrode array (MEA) was used, following the instructions in the iCell GlutaNeurons 01279 (FUJIFILM Cellular Dynamics, Inc.) package insert. Specifically, a CytoView MEA 24 (Axion BioSystems) plate was coated with 0.1% polyethyleneimine solution overnight at room temperature, washed with water, and dried. Next, the plate was further coated with medium containing 100 μg / mL laminin (Sigma-Aldrich) overnight at 4°C. The next day, the plate was incubated in 5% CO 2 The cells were left to stand for another hour in an incubator (37°C). iCell® GABAergic neurons and iCell GlutaNeurons 01279 were mixed in equal amounts and placed on the electrode section at 9.9 x 10 5 cells / cm 2 The next day, XCL-1 Mature Astrocytes (AM-001-1V) were placed on the electrode at a density of 2.2 x 10 5 cells / cm 2 Two days later, Comparative Compound 1 or Compound 7 was diluted with medium to a predetermined concentration and added (600 μL / well). Nothing was added to the non-treated group, and the cells were cultured in medium. N=6 wells for each group. Half of the medium was replaced every four days. On the 25th day of culture, the cells were incubated at 37°C, 5% CO for 15 minutes before adding KCl. 2Spontaneous neural activity was measured (pre-) using a Maestro Pro (Axion BioSystems). To induce excessive neural synchronization, 3 μL of 1 M KCl was added to 600 μL / well of culture medium to create a condition containing approximately 10 mM KCl. (Since BrainPhys medium is only disclosed to contain less than 5 mM KCl under basal conditions, it is not possible to accurately determine the final KCl concentration, so the value is stated as <10 mM) (Bardy C et al., Proc Natl Acad Sci USA. 2015. 112. E2725-E2734.). The analysis was performed using AxIS Navigator (version 2.0.4.21) and Neural Metric Tool (version 2.4.12). The network burst detection settings for Burst Detector Setting were Burst Detection Algorithm Inter-Spike Interval (ISI) Threshold, Minimum Number of Spikes (network bursts) 50, Maximum Inter-Spike Interval (network bursts) 100 ms, and Minimum Participating Electrodes (%) 35 (default settings).

[0100] Results: As shown in Figure 9A, after knockdown of endogenous TAU with two oligonucleotides over approximately 22 days, spontaneous neural activity was observed in the Pre neurons (Figure 9B, left). Next, KCl was added to induce synchronization of pathological excessive neural activity. In the no-treatment group, the number of network bursts (boxed) significantly increased (Figure 9B, right, and Figure 9C). Network bursts refer to the phenomenon of simultaneous neural activity observed at multiple electrodes in a single well (detection definition is described in the Methods section). We believe that a chronic increase in network bursts may lead to neurodegeneration. Therefore, we investigated whether endogenous TAU knockdown could correct the abnormal increase in network bursts. Prior treatment with 0.3 μM Comparative Compound 1 did not suppress the increase, but treatment with 3 μM Comparative Compound 1 suppressed the increase (Figure 9C). Furthermore, compound 7 at 1 μM was able to suppress the increase in network bursts ( FIG. 9C ). These results suggest that compound 7 can suppress excessive synchronization of neural activity by reducing TAU productive mRNA through an increase in TAU nonproductive mRNA.

[0101] 11. Concentration-Dependence Study II A concentration-dependence study was performed using SSO-type oligonucleotides and gapmer-type oligonucleotides with the same sequences. Productive and nonproductive mRNA and TAU protein were quantified, and the splice-switching activity and TAU protein knockdown activity were investigated.

[0102] <Method> In the iPS neuron culture method of Experiment 2, SSO Compound 7 or Compound 8, or comparative gapmer-type oligonucleotides Comparative Compound 2 or Comparative Compound 3, were treated with freeuptake (treatment for 15 days). Untreated samples were treated with d.w. to a final concentration of 0.1%. Comparative Compounds 2 and 3 were synthesized in the same manner as in Experiment 1.

[0103] To perform qPCR, 10 μL of lysis buffer (a mixture of 9.78 μL of lysis solution, 0.17 μL of RNase inhibitor, and 0.05 μL of gDNA remover) was added to the cells, and the mixture was left at room temperature for 5 minutes to decompose the genomic DNA and obtain an RNA-containing solution. Next, for reverse transcription, the 5X RT Master Mix, the RNA-containing solution, and dw were mixed and reacted at 37°C (15 minutes), 50°C (5 minutes), and 98°C (5 minutes). The cDNA solution was then diluted 4-fold with dw. Next, TAU, ACTB, and NfL were quantified using the qPCR method described in Experiment 4. The quantitative values ​​of TAU and NfL were corrected by the quantitative value of ACTB. The untreated group was plotted on a graph, with the untreated group set to 100%.

[0104] To quantify TAU protein, cells were solubilized in RIPA Buffer 1x (prepared solution) without protease inhibitors. Total protein and TAU protein concentrations were measured using the BCA kit (Nacalai Tesque) and HTRF® kits, as described in Experiment 7. Fluorescence signals were measured at 620 nm and 665 nm (detection filters) using an EnVision multimode plate reader (PerkinElmer) with excitation at 320 nm. The TAU protein quantification values ​​were divided by the total protein quantification values ​​measured by BCA, and the untreated values ​​were corrected to 100% and plotted on a graph.

[0105] <Results> SSO compounds 7 and 8 increased TAU nonproductive mRNA at concentrations on the order of several nM, and decreased TAU productive mRNA at concentrations of approximately 10 nM (Figures 10A and 10B). On the other hand, comparative gapmer-type compounds 2 and 3, which have the same sequences, decreased both nonproductive and productive mRNA at concentrations on the order of nM (Figures 10C and 10D). Although the gapmer-type oligonucleotides have the same sequences, they reduced both nonproductive and productive mRNAs, demonstrating that the SSO-type oligonucleotides of the present invention selectively reduced productive mRNA via splicing.

[0106] These experiments demonstrate that SSOs that increase exon 1B-containing TAU nonproductive mRNA reduce TAU protein levels, that this effect may be selective for excitatory neurons, and that they can suppress excessive neuronal synchronization, making them useful for treating or preventing TAU-related disorders.

Claims

1. A splice-switching oligonucleotide that binds to intron 1B of the TAU pre-mRNA.

2. A splice-switching oligonucleotide according to claim 1, which is capable of increasing the amount of TAU mRNA containing TAU exon 1B.

3. A splice switching oligonucleotide according to claim 1, capable of reducing the amount of TAU protein.

4. The splice-switching oligonucleotide of claim 1, comprising a sequence complementary to a portion of intron 1B of TAU pre-mRNA.

5. A splice switching oligonucleotide according to claim 1, comprising a sequence complementary to at least a portion of residues 6 to 24 of SEQ ID NO:

2.

6. The splice-switching oligonucleotide of claim 1, which is 16 to 20 bases in length.

7. A splice switching oligonucleotide according to claim 1, capable of selectively reducing the amount of TAU protein in excitatory neurons.

8. A splice-switching oligonucleotide according to claim 7, capable of reducing the amount of TAU protein in excitatory neurons by at least 5% more than the reduction in inhibitory neurons.

9. A pharmaceutical composition for treating or preventing a TAU-associated disease, comprising the splice-switching oligonucleotide according to any one of claims 1 to 8.

10. The pharmaceutical composition according to claim 9, wherein the TAU-related disease is tauopathy or epilepsy.

11. The pharmaceutical composition of claim 9, wherein the TAU-related disease is selected from the group consisting of Alzheimer's disease, vascular dementia, dementia with Lewy bodies, Parkinson's disease, amyotrophic lateral sclerosis, Down's syndrome, Pick's disease, chronic traumatic encephalopathy, progressive supranuclear palsy, basal ganglia degeneration, and myotonic dystrophy type 1.

12. The pharmaceutical composition of claim 9, wherein the TAU-related disease is selected from the group consisting of Dravet syndrome, tuberous sclerosis, periodic ataxia, CDFE syndrome, and DEE14 or 18.

13. The pharmaceutical composition of claim 9, wherein the TAU-related disease is selected from the group consisting of glaucoma and age-related macular degeneration.